GlaxoSmithKline Consumer Healthcare (GSKCH): GSK 9MCY21 Analyst Briefing Takeaways – By Darson Research

<ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Today, GSK conducted its analyst briefing to discuss the 9MCY21 results. Management also discussed future prospects. We summarize the conclusions as follows:</span></li><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">GSKCH profitability clocked in at PKR1,195mn (EPS PKR 3.75) up 6% QoQ in 3QCY2021, cumulating into 9MCY2021 profitability of PKR2,901mn (EPS PKR 9.11), up 22.4% YoY.</span></li><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Gross margin improved and posted at 26.3% in 9MCY2021 compared to 22.7% in SPLY due to CPI increase and cost efficient measures taken by company on supply sites coupled with product development.</span></li></ul>